GFAP and Alzheimer disease: In particular, the deletion of GFAP and vimentin in the APP/PS1 mouse model of AD increased the Aβ load and the number of dystrophic neurites, reinforcing the prominent role of astrocytes in limiting plaque growth and attenuating plaque-related dystrophic neurites98.